Stanford University: Leukemia trials
The registry lists 28 Leukemia studies with Stanford University as lead sponsor. 3 are open to participants now and 7 have results posted.
Phase 1 9Phase 2 10Phase 3 1No phase 10(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell MalignanciesRecruitingNCT06408194Phase 1
- AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasRecruitingNCT06340737Phase 1
- Bone Marrow Grafting for Leukemia and LymphomaEnrolling by invitationNCT00186147
- Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell TransplantationCompletedNCT03734601Phase 2Results posted
- Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
- Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT01769209Phase 2Results posted
- Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDSTerminatedNCT01442714Phase 2Results posted
- Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaTerminatedNCT01401322Phase 2Results posted
- Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)CompletedNCT00890929Phase 1/2Results posted
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AMLTerminatedNCT00568633Phase 3Results posted
- Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic LeukemiaActive, not recruitingNCT05993949Phase 1
- Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse EventsCompletedNCT05123001
- Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid LeukemiaCompletedNCT02856204
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-TransplantWithdrawnNCT02723435Phase 2
- Carfilzomib in Combination With Cyclophosphamide and Etoposide for ChildrenCompletedNCT02512926Phase 1
- Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01904643Phase 1
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT01835288Phase 2
- Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and VomitingWithdrawnNCT01492569Not applicable
- Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic LeukemiaWithdrawnNCT01162031Phase 2
- Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic LeukemiasCompletedNCT01144793
- Genome, Proteome and Tissue Microarray in Childhood Acute LeukemiaTerminatedNCT01108497
- Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent RemissionCompletedNCT00186381Phase 2
- Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic MalignanciesCompletedNCT00186342Not applicable
- Transplantation for Patients With Chronic Lymphocytic LeukemiaCompletedNCT00186303Not applicable
- Allo BMT in Advanced Leukemia or High Grade LymphomaCompletedNCT00186290Not applicable
- Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)TerminatedNCT00185523
- Bevacizumab in Treating Patients With Myelodysplastic SyndromeCompletedNCT00022048Phase 1/2